RecruitingEarly Phase 1NCT06002477

Attentional Mechanisms in SCD

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vanderbilt University Medical Center
Principal Investigator
Paul Newhouse, MD
Vanderbilt University Medical Center
Intervention
Mecamylamine Challenge(drug)
Enrollment
80 enrolled
Eligibility
55 years · All sexes
Timeline
2025 – 2028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06002477 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease →

← Back to all trials